Fa	xed prescriptions will only b	pe accepted from a prescriber. P	atients must bring an	original prescription to the pharm	acy, and cannot fax thes	se referral forms to Send	erra.	
6		Osteoarthritis Enrollment Form	Prescriber:			NPI:		
		Lin oliment i orin	Supervising Physician:			NPI:	NPI:	
		Physician Offices Call: 855-460-7928	Address:			Tax ID:		
Specialty Pharmacy		F 000 777 5045	Phone:		Fax:	'		
		Fax: 888-777-5645	Contact:					
This prescription form is	to be sent & received via fax		DATIENT IN	IEODMATION				
PATIENT INFORMATION Name: □ M □ F □ Trans M □ Trans F □ Other □ DOB: , , , SS#: SS#:								
Street:			City:	State:				
Phone: Alt. Phone:								
PRESCRIPTION Has the patient received a loading dose/starter kit? Yes Start Date:// DNO SHIP TO: Patient's Home Doctor's Office Other:								
Has the patient re Drug	eceived a loading dos	e/starter kit? └ Yes Start [Date://_	□ _{No} SHIP TO: □ Directions & Qu		Doctor's Office □	Other: Refills	
Drug		☐ Inject 3 ml I	^ into each knoo		iantity		Reillis	
Durolane [®]	Syringe	Inject 3 mL I	- Carrier Control of Carrier Con					
Euflexxa®	☐ Pre-filled Syringe	,	□ Inject 2 mL IA into each knee at weekly intervals for 3 weeks (Quantity: 6) □ Inject 2 mL IA into □ Left knee OR □ Right knee at weekly intervals for 3 weeks (Quantity: 3)					
Gel-One®	☐ Pre-filled Syringe	Pre-filled Syringe Inject 3 mL IA into each knee as directed (Quantity: 2) Inject 3 mL IA into Left knee OR Right knee as directed (Quantity: 1)						
Gelsyn-3®	☐ Pre-filled Syringe	Digit 2 ml. IA into each knee at weekly intervals for 3 weeks (Quantity: 6)						
Hyalgan®	Pre-filled Syringe	☐ Inject 2 mL I						
Hymovis [®]	☐ Pre-filled Syringe	☐ Inject 3 mL IA into each knee at day 0 and day 7 (Quantity: 4) ☐ Inject 3 mL IA into ☐ Left knee OR ☐ Right knee at day 0 and day 7 (Quantity: 2)						
	☐ Inject 3 mL IA into □ Left knee OR □ Right knee at day 0 and day 7 (Quantity: 2) ☐ Inject 2 mL IA into each knee at weekly intervals for 3 weeks (Quantity: 6)							
Orthovisc®	Pre-filled Syringe	☐ Inject 2 mt IA into ☐ Left knee ○R ☐ Pight knee at weekly intervals for 3 weeks (Quantity: 3)						
Supartz FX®	☐ Pre-filled Syringe	☐ Inject 2.5 mL☐ Inj	□ Inject 2.5 mL IA into each knee at weekly intervals for 3 weeks (Quantity: 6) □ Inject 2.5 mL IA into □ Left knee OR □ Right knee at weekly intervals for 3 weeks (Quantity: 3) □ Inject 2.5 mL IA into □ ach knee at weekly intervals for 5 weeks (Quantity: 10)					
Synvisc®	☐ Pre-filled Syringe		, , , , , , , , , , , , , , , , , , , ,					
Synvisc-One®	☐ Pre-filled Syringe	☐ Inject 6 mL I.	☐ Inject 6 mL IA into each knee as directed (Quantity: 2) ☐ Inject 6 mL IA into ☐ Left knee OR ☐ Right knee as directed (Quantity: 1)					
Visco-3™	☐ Pre-filled Syringe	☐ Inject 2.5 mL	□ Inject 2.5 mL IA into each knee at weekly intervals for 3 weeks (Quantity: 6) □ Inject 2.5 mL IA into □ Left knee OR □ Right knee at weekly intervals for 3 weeks (Quantity: 3)					
MEDICAL INFORMATION ***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY***								
PREVIOUS THE		Tried & Failed (De		Not Tolerated:		ontraindication:		
<u> </u>	· · · · · · · · · · · · · · · · · · ·	<u> </u>)					
<u> </u>	· · · · · · · · · · · · · · · · · · ·	<u> </u>)					
<u>-</u>)					
☐ M15.0 Primary generalized osteoarthritis ☐ M17.11 Unilateral primary osteoarthritis, right knee								
□ M17.12 Unilateral primary osteoarthritis, left knee □ M17.9 Osteoarthritis of knee, unspecified □ M19.90 Unspecified osteoarthritis, unspecified site □ M19.91 Primary osteoarthritis, unspecified site								
		•		□ M19.91 Primary os	teoarthritis, unspeci	fied site		
Date of Diagnosi	s: / /		Allergies:		<u></u>			
Last x-ray date:// Any changes with latest x-ray? ☐ Yes ☐ No								
Additional Clinical	Information:							
PRESCRIBER SIGNATURE To Proceedings of the form and difference of the process of								
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.								
Prescriber: CONFIDENTIALITY NOTICE Date:/								
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are								
not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.								

Osteoarthritis Enrollment (Rev. 7/8/2021)